Literature DB >> 23129293

Disturbance of serotonergic neurotransmission in patients with postmyocardial infarction and depression.

Gabriel Manjarrez-Gutiérrez1, Rodolfo Ramírez-Campillo, Gabriela Borrayo-Sánchez, Jorge Hernández-Rodríguez.   

Abstract

The objective of this study was to assess the hypothesis that patients who develop depression after myocardial infarction (MI) have a lower level of brain serotonergic neurotransmission through measurement of plasma free fraction of L-tryptophan and intensity-dependence auditory-evoked potentials (IDAEPs). A cross-sectional study was carried out in 74 adults after MI. Thirty-four patients suffered from depression and 40 patients did not demonstrate depressive symptoms. We measured the free fraction, bound and total plasma L-tryptophan, and neutral amino acids as well as recording IDAEPs. Patients who developed depression after MI showed a significantly lower level in the free fraction of L-tryptophan and in the ratios of free fraction of L-tryptophan/total L-tryptophan and free fraction of L-tryptophan/neutral amino acids. It is noteworthy that the slope of the amplitude/stimulus intensity functions (ASF slope) of the N1/P2 component was significantly higher post-MI in depressed patients. Higher ASF slope of the N1/P2 component associated with a low free fraction of L-tryptophan in plasma reflect a low brain serotonergic neurotransmission. These findings suggest an important deterioration of brain serotonergic activity as a pathophysiological mechanism in post-MI patients for the development of clinical depression. Therefore, we propose these biochemical and electrophysiological procedures as noninvasive clinical indicators of brain serotonergic activity in these patients.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23129293     DOI: 10.1007/s11011-012-9355-1

Source DB:  PubMed          Journal:  Metab Brain Dis        ISSN: 0885-7490            Impact factor:   3.584


  36 in total

Review 1.  Role of serotonin in depression.

Authors:  H Y Meltzer
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

2.  Lower central nervous system serotonergic function and risk of cardiovascular disease: where are we, what's next?

Authors:  Redford B Williams
Journal:  Stroke       Date:  2007-07-12       Impact factor: 7.914

3.  Auditory-evoked potentials as indicator of brain serotonergic activity--first evidence in behaving cats.

Authors:  G Juckel; M Molnár; U Hegerl; V Csépe; G Karmos
Journal:  Biol Psychiatry       Date:  1997-06-15       Impact factor: 13.382

Review 4.  The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions.

Authors:  C B Nemeroff
Journal:  Mol Psychiatry       Date:  1996-09       Impact factor: 15.992

Review 5.  Impact of psychological factors on the pathogenesis of cardiovascular disease and implications for therapy.

Authors:  A Rozanski; J A Blumenthal; J Kaplan
Journal:  Circulation       Date:  1999-04-27       Impact factor: 29.690

Review 6.  Intensity dependence of auditory evoked potentials as an indicator of central serotonergic neurotransmission: a new hypothesis.

Authors:  U Hegerl; G Juckel
Journal:  Biol Psychiatry       Date:  1993-02-01       Impact factor: 13.382

7.  Augmenting/reducing: an adaptive switch mechanism to cope with incoming signals in healthy subjects and psychiatric patients.

Authors:  L von Knorring; K Monakhov; C Perris
Journal:  Neuropsychobiology       Date:  1978       Impact factor: 2.328

8.  Symptoms of depression, acute myocardial infarction, and total mortality in a community sample.

Authors:  J C Barefoot; M Schroll
Journal:  Circulation       Date:  1996-06-01       Impact factor: 29.690

Review 9.  [Post-myocardial infarction depression].

Authors:  E García Vicente; V Del Villar Sordo; E L García Y García
Journal:  An Med Interna       Date:  2007-07

10.  Myocardial protein turnover in patients with coronary artery disease. Effect of branched chain amino acid infusion.

Authors:  L H Young; P H McNulty; C Morgan; L I Deckelbaum; B L Zaret; E J Barrett
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.